Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. Bone Marrow Transplant 1999 Nov;24(10):1043-51
Date
12/01/1999Pubmed ID
10578153DOI
10.1038/sj.bmt.1702020Scopus ID
2-s2.0-0032732523 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Patients with recurrent leukemia after an allogeneic hematopoietic stem cell transplant may be treated with donor lymphocyte infusions (DLI). The transfusion of lymphocytes from the original hematopoietic stem cell donor induces remission in approximately one third of relapsed AML cases and 80% of relapsed CML. DLI may be complicated by delayed and sometimes lethal graft-versus-host disease (GVHD). In an attempt to avoid this complication, several centers have initiated DLI trials in which the infused lymphocytes carry a suicide gene, herpes simplex thymidine kinase (HStk), which confers sensitivity to ganciclovir (GCV). In the event of severe GVHD, administration of GCV should terminate or ameliorate GVHD.
Author List
Burt RK, Drobyski WR, Traynor AE, Link CJ JrAuthor
William R. Drobyski MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
GanciclovirGraft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Lymphocyte Transfusion
Simplexvirus
Thymidine Kinase
Transfection